PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
05 April 2024 - 7:04AM
PROCEPT BioRobotics® Corporation (Nasdaq: PRCT), a surgical
robotics company focused on advancing patient care by developing
transformative solutions in urology, announced today it will host
an in-person investor event on Friday, May 3, 2024, at the Grand
Hyatt Hotel in San Antonio, TX at the American Urological
Association Annual Meeting from 8:00am to 9:30am Central Time.
Members of PROCEPT BioRobotics’ management team presenting
include:
- Reza Zadno – President & Chief
Executive Officer
- Kevin Waters – Executive VP & Chief
Financial Officer
- Sham Shiblaq – Executive VP & Chief
Commercial Officer
- Barry Templin – Executive VP, Technology
and Clinical Development
Clinical perspectives will also be provided by the following
physicians:
- Dr. Inderbir Gill, Founding Executive Director
for USC Urology and Chairman of Urological Cancer Surgery at
Keck School of Medicine of USC
- Dr. Brian Helfand, Division of Urology,
NorthShore University Health System
- Dr. Lewis S. Kriteman, Partner and Executive
VP, Georgia Urology
A live webcast of the event, as well as an archived recording,
will be available on the “Investors” section of the Company’s
website at https://ir.procept-biorobotics.com/. The webcast will be
archived and available for replay for at least 90 days after the
event.
About PROCEPT BioRobotics CorporationPROCEPT
BioRobotics is a surgical robotics company focused on advancing
patient care by developing transformative solutions in urology.
PROCEPT BioRobotics develops, manufactures and sells the AquaBeam
Robotic System, an advanced, image-guided, surgical robotic system
for use in minimally invasive urologic surgery with an initial
focus on treating benign prostatic hyperplasia, or BPH. BPH is the
most common prostate disease and impacts approximately 40 million
men in the United States. PROCEPT BioRobotics designed Aquablation
therapy to deliver effective, safe and durable outcomes for males
suffering from lower urinary tract symptoms, or LUTS, due to BPH
that are independent of prostate size and shape or surgeon
experience. The Company has developed a significant and growing
body of clinical evidence, which includes nine clinical studies and
over 150 peer-reviewed publications, supporting the benefits and
clinical advantages of Aquablation therapy.
Important Safety Information
All surgical treatments have inherent and associated side
effects. For a list of potential side effects
visit https://aquablation.com/safety-information/.
Investor Contact:Matt BacsoVP, Investor
Relations and Business
Operationsm.bacso@procept-biorobotics.com
PROCEPT BioRobotics (NASDAQ:PRCT)
Historical Stock Chart
From Apr 2024 to May 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
Historical Stock Chart
From May 2023 to May 2024